toll like receptor 4

[키워드] 95% CI 95% confidence interval ACE2 ACE2angiotensin-converting enzyme 2 activities Acute kidney injury acute respiratory syndrome Admission adult COVID-19 patient adverse events Affect angiotensin-converting enzyme 2 Anti-inflammatory anti-inflammatory agents assigned caffeic acid phenethyl ester CAPEcaffeic acid phenethyl ester Care clinical benefit Clinical improvement Control control group Controlled clinical trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19coronavirus disease 2019 defined dose Effect enrolled Evidence evidenced group High dose Hospital stay Hospitalized hospitalized COVID-19 hospitalized COVID-19 patients human transmembrane protease 2 immune immunoregulation Inflammatory intensive care lower dose median need for oxygen NF-kBnuclear factor-kappa B nuclear factor-kappa B Odds ratio Open-label outcome Oxygen therapy p21-activated kinase 1 PAK1 PAK1 blocker PAK1p21-activated kinase 1 Patient post-intervention primary end point promote Propolis Randomized receive reduce reduction in SARS-CoV-2 SARS-CoV-2severe acute respiratory syndrome coronavirus 2 secondary Seven severe acute respiratory syndrome coronavirus 2 significantly single-center Standard standard care targets tested therapeutic therapy TLR4toll like receptor 4 TMPRSS2 TMPRSS2. TMPRSS2human transmembrane protease 2 toll like receptor 4 treated Treatment Trial vasoactive drugs
[DOI] 10.1016/j.biopha.2021.111526 PMC 바로가기 [Article Type] Randomized Controlled Trial